Theratechnologies (THTX) Competitors $3.24 +0.02 (+0.47%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. RLAY, BCAX, TLRY, ORGO, XNCR, MRVI, TSHA, TRML, BCYC, and TYRAShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), Tilray Brands (TLRY), Organogenesis (ORGO), Xencor (XNCR), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), Tourmaline Bio (TRML), Bicycle Therapeutics (BCYC), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Its Competitors Relay Therapeutics Bicara Therapeutics Tilray Brands Organogenesis Xencor Maravai LifeSciences Taysha Gene Therapies Tourmaline Bio Bicycle Therapeutics Tyra Biosciences Theratechnologies (NASDAQ:THTX) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do insiders and institutionals believe in THTX or RLAY? 97.0% of Relay Therapeutics shares are held by institutional investors. 4.9% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer THTX or RLAY? Relay Therapeutics has a consensus price target of $17.25, suggesting a potential upside of 386.60%. Given Relay Therapeutics' higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Which has more volatility and risk, THTX or RLAY? Theratechnologies has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Is THTX or RLAY more profitable? Relay Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Theratechnologies' return on equity of 0.00% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-10.85% N/A -9.83% Relay Therapeutics N/A -41.49%-37.43% Which has stronger valuation and earnings, THTX or RLAY? Theratechnologies has higher revenue and earnings than Relay Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$85.87M1.73-$8.31M-$0.19-17.03Relay Therapeutics$10.01M61.06-$337.71M-$1.95-1.82 Does the media refer more to THTX or RLAY? In the previous week, Relay Therapeutics had 2 more articles in the media than Theratechnologies. MarketBeat recorded 4 mentions for Relay Therapeutics and 2 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 1.44 beat Relay Therapeutics' score of 0.23 indicating that Theratechnologies is being referred to more favorably in the media. Company Overall Sentiment Theratechnologies Positive Relay Therapeutics Neutral SummaryRelay Therapeutics beats Theratechnologies on 9 of the 16 factors compared between the two stocks. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$148.75M$3.13B$5.69B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-17.0320.8430.6625.56Price / Sales1.73365.80465.14116.21Price / CashN/A43.0338.2159.48Price / Book-5.888.659.016.14Net Income-$8.31M-$54.65M$3.25B$264.98M7 Day Performance1.41%6.60%4.84%2.75%1 Month Performance3.03%9.54%6.85%3.15%1 Year Performance137.87%14.25%30.51%25.14% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$3.24+0.5%N/A+135.9%$148.75M$85.87M-17.03140Positive NewsShort Interest ↓RLAYRelay Therapeutics1.9373 of 5 stars$3.65+8.6%$17.67+384.0%-47.4%$576.05M$10.01M-1.64330BCAXBicara Therapeutics2.0141 of 5 stars$11.12+5.6%$31.86+186.5%N/A$574.27MN/A0.0032News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionTLRYTilray Brands2.4134 of 5 stars$0.61+6.9%$1.92+215.3%-38.5%$572.39M$821.31M-0.262,650Gap UpORGOOrganogenesis4.2232 of 5 stars$4.60+2.0%$6.50+41.3%+82.2%$572.11M$482.04M-27.06950XNCRXencor3.6195 of 5 stars$7.95-0.4%$28.00+252.2%-51.4%$567.94M$110.49M-2.60280MRVIMaravai LifeSciences3.721 of 5 stars$2.27+2.3%$6.64+192.5%-68.4%$565.34M$259.18M-1.99610Analyst ForecastTSHATaysha Gene Therapies3.5269 of 5 stars$2.71+3.0%$8.17+201.4%+27.3%$564.56M$8.33M-7.97180News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTRMLTourmaline Bio2.4173 of 5 stars$21.59-0.8%$49.33+128.5%+65.7%$558.91MN/A-6.7344News CoverageEarnings ReportAnalyst ForecastBCYCBicycle Therapeutics3.4855 of 5 stars$8.05+0.8%$24.22+200.9%-66.7%$553.34M$35.28M-2.56240Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionTYRATyra Biosciences2.4578 of 5 stars$10.65+2.7%$30.83+189.5%-50.4%$550.54MN/A-6.5320News CoveragePositive NewsEarnings ReportUpcoming EarningsGap Up Related Companies and Tools Related Companies RLAY Competitors BCAX Competitors TLRY Competitors ORGO Competitors XNCR Competitors MRVI Competitors TSHA Competitors TRML Competitors BCYC Competitors TYRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access